Login
Home
Charts
Search
Watchlist
Products

Honasa Consumer Ltd

HONASA·NSE
473.65+0.01%Tue, 22 Sept '26

Honasa Consumer Ltd

HONASA
NSE
473.65
+0.01%
|Tue, 22 Sept '26
SOICxStockScans Reports
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
15,517Cr
Close
Close Price
475.95
Industry
Industry
New age - Platform - E-Retail
PE
Price To Earnings
62.22
PS
Price To Sales
6.08
Revenue
Revenue
2,553Cr
Rev Gr TTM
Revenue Growth TTM
21.08%
PAT Gr TTM
PAT Growth TTM
238.06%

Quarterly Results

Consolidated
Standalone
Numbers
Percentage
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
496488471554462518534595538602657756
Growth YoY
Revenue Growth YoY%
20.927.821.519.3-6.96.013.37.416.516.223.127.0
Expenses
ExpensesCr
456454438508493491507549490536580646
Operating Profit
Operating ProfitCr
40343346-31262746486677110
OPM
OPM%
8.17.17.08.3-6.75.05.17.78.810.911.814.6
Other Income
Other IncomeCr
71119192019212420161923
Interest Expense
Interest ExpenseCr
233333333333
Depreciation
DepreciationCr
681091113121112111111
PBT
PBTCr
39353952-24293256536782119
Tax
TaxCr
109912-6371414171229
PAT
PATCr
29263040-1926254139506990
Growth YoY
PAT Growth YoY%
93.8263.3118.862.9-163.10.5-18.02.7311.192.9178.0118.8
NPM
NPM%
5.95.36.57.3-4.05.04.76.97.38.310.612.0
EPS
EPS
1.00.81.01.2-0.60.80.81.31.21.52.12.8
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
496488471554462518534595538602657756
Growth YoY
Revenue Growth YoY%
20.927.821.519.3-6.96.013.37.416.516.223.127.0
Expenses
ExpensesCr
456454438508493491507549490536580646
Operating Profit
Operating ProfitCr
40343346-31262746486677110
OPM
OPM%
8.17.17.08.3-6.75.05.17.78.810.911.814.6
Other Income
Other IncomeCr
71119192019212420161923
Interest Expense
Interest ExpenseCr
233333333333
Depreciation
DepreciationCr
681091113121112111111
PBT
PBTCr
39353952-24293256536782119
Tax
TaxCr
109912-6371414171229
PAT
PATCr
29263040-1926254139506990
Growth YoY
PAT Growth YoY%
93.8263.3118.862.9-163.10.5-18.02.7311.192.9178.0118.8
NPM
NPM%
5.95.36.57.3-4.05.04.76.97.38.310.612.0
EPS
EPS
1.00.81.01.2-0.60.80.81.31.21.52.12.8

Profit & Loss

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
4609431,4931,9202,0672,3922,553
Growth
Revenue Growth%
105.158.228.67.715.721.1
Expenses
ExpensesCr
1,7949321,4701,7831,9982,1562,252
Operating Profit
Operating ProfitCr
-1,334112313769236301
OPM
OPM%
-290.01.21.57.13.39.911.8
Other Income
Other IncomeCr
1221-13250797977
Interest Expense
Interest ExpenseCr
1379131313
Depreciation
DepreciationCr
272531454444
PBT
PBTCr
-1,32522-14114790257321
Tax
TaxCr
881037175772
PAT
PATCr
-1,33214-15111173200249
Growth
PAT Growth%
101.1-1,145.3173.2-34.2175.4238.1
NPM
NPM%
-289.61.5-10.15.83.58.49.8
EPS
EPS
-13,02,899.80.5-4.73.62.26.27.7
Financial YearMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
4609431,4931,9202,0672,3922,553
Growth
Revenue Growth%
105.158.228.67.715.721.1
Expenses
ExpensesCr
1,7949321,4701,7831,9982,1562,252
Operating Profit
Operating ProfitCr
-1,334112313769236301
OPM
OPM%
-290.01.21.57.13.39.911.8
Other Income
Other IncomeCr
1221-13250797977
Interest Expense
Interest ExpenseCr
1379131313
Depreciation
DepreciationCr
272531454444
PBT
PBTCr
-1,32522-14114790257321
Tax
TaxCr
881037175772
PAT
PATCr
-1,33214-15111173200249
Growth
PAT Growth%
101.1-1,145.3173.2-34.2175.4238.1
NPM
NPM%
-289.61.5-10.15.83.58.49.8
EPS
EPS
-13,02,899.80.5-4.73.62.26.27.7

Balance Sheet

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
00136324325325
Reserves
ReservesCr
-1,765-1,087-1,3237718551,086
Current Liabilities
Current LiabilitiesCr
93208289414490568
Non Current Liabilities
Non Current LiabilitiesCr
1,97512281123121112
Total Liabilities
Total LiabilitiesCr
3031,0359771,6321,7902,092
Current Assets
Current AssetsCr
2756026411,1281,012959
Non Current Assets
Non Current AssetsCr
274333365047791,134
Total Assets
Total AssetsCr
3031,0359771,6321,7902,092
Financial YearMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
00136324325325
Reserves
ReservesCr
-1,765-1,087-1,3237718551,086
Current Liabilities
Current LiabilitiesCr
93208289414490568
Non Current Liabilities
Non Current LiabilitiesCr
1,97512281123121112
Total Liabilities
Total LiabilitiesCr
3031,0359771,6321,7902,092
Current Assets
Current AssetsCr
2756026411,1281,012959
Non Current Assets
Non Current AssetsCr
274333365047791,134
Total Assets
Total AssetsCr
3031,0359771,6321,7902,092

Cash Flow

Consolidated
Standalone
Financial YearMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
45-52235102141
Investing Cash Flow
Investing Cash FlowCr
-50043-470-145-17
Financing Cash Flow
Financing Cash FlowCr
481-14337-31-38
Net Cash Flow
Net Cash FlowCr
26-23102-7486
Free Cash Flow
Free Cash FlowCr
43-6322486134
CFO To PAT
CFO To PAT%
308.734.1212.9140.670.6
CFO To EBITDA
CFO To EBITDA%
389.1-226.5171.7149.159.9
Financial YearMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
45-52235102141
Investing Cash Flow
Investing Cash FlowCr
-50043-470-145-17
Financing Cash Flow
Financing Cash FlowCr
481-14337-31-38
Net Cash Flow
Net Cash FlowCr
26-23102-7486
Free Cash Flow
Free Cash FlowCr
43-6322486134
CFO To PAT
CFO To PAT%
308.734.1212.9140.670.6
CFO To EBITDA
CFO To EBITDA%
389.1-226.5171.7149.159.9

Ratios

Consolidated
Standalone
Financial YearMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
13,0357,5489,70115,517
Price To Earnings
Price To Earnings
116.5103.648.562.2
Price To Sales
Price To Sales
6.83.64.16.1
Price To Book
Price To Book
11.96.46.911.0
EV To EBITDA
EV To EBITDA
92.5107.340.851.8
Profitability Ratios
Profitability Ratios
GPM
GPM%
59.267.867.767.567.767.967.9
OPM
OPM%
-290.01.21.57.13.39.911.8
NPM
NPM%
-289.61.5-10.15.83.58.49.8
ROCE
ROCE%
-700.9-2.512.312.77.817.517.5
ROE
ROE%
75.5-1.312.710.16.214.214.2
ROA
ROA%
-440.21.4-15.56.84.19.69.6
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Financial YearMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
13,0357,5489,70115,517
Price To Earnings
Price To Earnings
116.5103.648.562.2
Price To Sales
Price To Sales
6.83.64.16.1
Price To Book
Price To Book
11.96.46.911.0
EV To EBITDA
EV To EBITDA
92.5107.340.851.8
Profitability Ratios
Profitability Ratios
GPM
GPM%
59.267.867.767.567.767.967.9
OPM
OPM%
-290.01.21.57.13.39.911.8
NPM
NPM%
-289.61.5-10.15.83.58.49.8
ROCE
ROCE%
-700.9-2.512.312.77.817.517.5
ROE
ROE%
75.5-1.312.710.16.214.214.2
ROA
ROA%
-440.21.4-15.56.84.19.69.6
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Honasa Consumer Ltd is India’s largest digital-first house of beauty and personal care (BPC) brands - a company that spots an unmet consumer need, builds a brand around it, and scales it online before taking it into physical stores. It was founded in 2016 by Varun and Ghazal Alagh with the launch of Mamaearth, a toxin-free personal care brand for young Indian families, and has since expanded into a portfolio of seven distinct brands, each targeting a different consumer, price point and need-state. The recurring approach is a repeatable playbook: use data and AI to identify a white space, develop a product that wins in blind tests against global rivals, build awareness through digital content and influencers, and then - once consumer pull is proven - roll it out across e-commerce, quick-commerce and a growing network of offline distributors. # Business segments A single engine - a house of BPC brands - built on one repeatable playbook, with a flagship brand that funds the rest and a new nutraceuticals leg taking shape. ## 1. Mamaearth: the flagship that built the house **A toxin-free, nature-inspired personal care brand that became India’s third-largest skincare brand by turning traditional Indian DIY ingredients into modern formats - and it still sets the pace for the portfolio.** - **Built on cultural familiarity** - the brand formulates products around ingredients Indians have used for generations, such as ubtan, rice, onion and multani mitti, giving it a connection that management says no international brand can replicate from its own DNA. - **Hero products pull the brand** - a handful of products including Ubtan Face Wash, Onion Shampoo and Rice Face Wash grow twice as fast as the brand itself, and Mamaearth’s brand power index for face wash and shampoo has reached its highest level in three years. - **Omnichannel reach with offline momentum** - present in roughly 200,000 retail outlets as of FY26, with offline contributing almost 45% of sales split roughly 40:60 between Modern Trade and General Trade; the brand sees potential to reach half a million outlets over the next three to five years. - **Premium positioning without the luxury price** - pricing starts from Rs. 100, deliberately staying above mass-market price points and avoiding the sub-Rs. 20 segment that defines FMCG-led BPC, which helps protect brand aspiration. - **Purpose as a differentiator** - it is Asia’s first MADE SAFE-certified brand, is plastic-positive, and has planted over 910,000 trees through its ‘Plant Goodness’ initiative, linking every purchase to a social cause. ## 2. The Derma Co.: the science-led engine for active-ingredient skincare **A dermatologist-collaborated brand that created the “active” proposition in Indian BPC, delivering targeted solutions for acne and pigmentation with clearly labelled ingredient concentrations - and it is already a Rs. 500 Crore-plus brand.** - **First-mover in actives** - the brand pioneered the active-ingredient skincare category in India by putting concentrations of ingredients like Salicylic Acid, Niacinamide and Kojic Acid directly on the label, formulated specifically for Indian skin and weather. - **Products that win in blind tests** - its serums were preferred significantly over both a leading Indian brand and a leading international brand in blind testing, and its Anti Hairfall Shampoo scored a likeability of 74 versus a rival’s 46. - **Chemist-led offline distribution** - of its 30,000-plus General Trade outlets, half are chemist shops, giving the brand a medical-halo effect that reinforces its science-backed positioning. - **Prestige pricing with innovation to match** - priced at more than twice the cost of other ranges, it has introduced first-to-India formats like Vitamin C Microneedle Serum Shot, justifying the premium through product superiority. ## 3. The younger brand portfolio: four distinct bets on specific cohorts **Aqualogica, Dr. Sheth’s, BBlunt and Staze each target a sharply defined consumer - Gen Z hydration, botanical-actives fusion, salon-quality haircare at home, and long-wear makeup - and together they are growing at nearly 40%.** - **Aqualogica: hydration for the Indian climate** - built around proprietary Water Lock Technology™, it combines fruit extracts with active ingredients in a vegan, cruelty-free range aimed at Gen Z; it reached a Rs. 180 Crore annual revenue run-rate within 19 months of launch. - **Dr. Sheth’s: three generations of skin science** - acquired in early 2022 and scaled over 30x in 25 months, it blends potent actives with soothing botanicals like Kesar and Haldi, drawing on over 90 years of family cosmetology expertise. - **BBlunt: salon credentials in a bottle** - acquired in 2022, its product business has grown more than 4x in three years and established leadership in online hairstyling; it also runs salons and has certified over 15,000 underprivileged women through its Shine Academy. - **Staze: the newest bet on colour cosmetics** - launched in March 2024 with C-Lock Technology™ promising 12-hour wear, it was co-created with 43 beauty professionals and targets 18-24-year-old Indian women with products averaging under Rs. 300. ## 4. Reginald Men: the acquired entry into male skincare **A fast-growing men’s sunscreen brand acquired in January 2026 that doubled its revenue year-on-year and crossed a Rs. 100 Crore annual run-rate in its first quarter under Honasa - opening the male personal care category for the house.** - **Sunscreen-first, South India-strong** - it is the number one men’s sunscreen brand on Google, with over 80% of sales coming from South India, and it is now being expanded into Maharashtra using content-led playbooks and quick-commerce. - **Acquired with a profitability track record** - in the twelve months before acquisition, it had a topline of over Rs. 70 Crore with nearly 25% EBITDA, meaning it arrived already capital-efficient and margin-accretive. - **Plugged into the house playbook** - the brand is being scaled using the same digital-first distribution and content engine that built Mamaearth and The Derma Co., with a focus on e-commerce and quick-commerce before offline expansion. ## 5. Nutraceuticals: the inside-out beauty bet under construction **A new leg being built through the acquisition of Fluence Pharma and the creation of a wholly owned subsidiary, Honasa Health, to sell vitamin and supplement kits that treat hair fall and acne from the inside - paired with topical products from the existing brands.** - **Dermatologist-sold, evidence-backed** - Fluence Pharma sells condition-specific OTC supplement kits under brands like Hair Fact and Skin Fact exclusively through a network of over 3,000 dermatologists, with over ten years of in-clinic evidence and hair-focused solutions contributing more than 70% of revenue. - **A large, growing market** - the Indian vitamins, minerals and supplements segment was over Rs. 16,000 Crore in FY25 and growing at an 11% compound annual rate, giving the new business a sizeable addressable market from day one. - **Two-channel strategy** - Fluence will continue its dermatologist-led prescription route, while the new subsidiary Honasa Health will build a direct-to-consumer brand combining topical products with nutraceutical regimes for conditions like hair fall and acne. # Group structure and partners **Honasa Consumer Ltd is the listed parent, with a growing family of subsidiaries acquired or created to house individual brands and new business lines - and two legacy entities are being merged back into the parent.** - **BTM Ventures (Reginald Men)** - 95% acquired in January 2026, with the remaining 5% to be bought after 12 months based on pre-agreed valuation criteria. - **Fluence Pharma** - board approval received in June 2026 to acquire a 58% stake, with the remaining 42% to be acquired in two tranches over five to seven years. - **Honasa Health** - incorporated as a wholly owned subsidiary in July 2026 to run the B2C nutraceuticals business. - **Couch Commerce (Fang Oral Care)** - a \~25% stake acquired in December 2025 via compulsory convertible preference shares, representing a participation route into oral care when internal bandwidth for brand creation was insufficient. - **Fusion Cosmeceutics and Just4Kids** - two wholly owned subsidiaries being merged into Honasa Consumer Ltd under a scheme of amalgamation approved by the NCLT in mid-2025, with the appointed date back in May 2023. - **International subsidiaries** - the group has wholly owned entities in Dubai and Indonesia, and a subsidiary for the BBlunt salon business in India; the Dubai entity is involved in ongoing arbitration with a former distributor.

Documents — Honasa Consumer Ltd

  • Q1 FY2027 Earnings Call Transcript (Jun 2026, PDF): https://www.stockscans.in/document/uptjbvgh81ayefu6zfui8t2z.pdf
  • Q4 FY2026 Earnings Call Transcript (Mar 2026, PDF): https://www.stockscans.in/document/0hxe1708i2uq82x591pbmzcj.pdf
  • Q3 FY2026 Earnings Call Transcript (Dec 2025, PDF): https://www.stockscans.in/document/g1jlmakbmp8ap8a368agcqo4.pdf
  • Q2 FY2026 Earnings Call Transcript (Sep 2025, PDF): https://www.stockscans.in/document/t5uzsxuzym0jvfied010pw2n.pdf
  • Q1 FY2026 Earnings Call Transcript (Jun 2025, PDF): https://www.stockscans.in/document/i50jycfyqg0g5ytall1cwods.pdf
  • Q4 FY2025 Earnings Call Transcript (Mar 2025, PDF): https://www.stockscans.in/document/1jinfimxzwzt24rf4ie9t1n8.pdf
  • Q3 FY2025 Earnings Call Transcript (Dec 2024, PDF): https://www.stockscans.in/document/ztnvv0z4c116ym8uhfhldncp.pdf
  • Q2 FY2025 Earnings Call Transcript (Sep 2024, PDF): https://www.stockscans.in/document/f7kzowuuc8gvwtccylu1e6up.pdf
  • Q1 FY2027 Quarterly Result (Jun 2026, PDF): https://www.stockscans.in/document/m2uva55fnsut26nywuqekvxa.pdf
  • Q4 FY2026 Quarterly Result (Mar 2026, PDF): https://www.stockscans.in/document/ez5o0ou54kq8e4ej2rpwqzok.pdf
  • Q3 FY2026 Quarterly Result (Dec 2025, PDF): https://www.stockscans.in/document/g8oqtthd0pd4l34r1tv7w8yb.pdf
  • Q2 FY2026 Quarterly Result (Sep 2025, PDF): https://www.stockscans.in/document/9avy7hoyiqmoaovhjnwka8zk.pdf
  • Q1 FY2026 Quarterly Result (Jun 2025, PDF): https://www.stockscans.in/document/c2nn5vgj2stbvghi0ycqphl9.pdf
  • Q4 FY2025 Quarterly Result (Mar 2025, PDF): https://www.stockscans.in/document/fw16egkqi9k3bd59worj9zzr.pdf
  • Q3 FY2025 Quarterly Result (Dec 2024, PDF): https://www.stockscans.in/document/nltuu2jjaqx11xvg7v7pi3h2.pdf
  • Q2 FY2025 Quarterly Result (Sep 2024, PDF): https://www.stockscans.in/document/3cw4p7qe4dhdc7sfgs1qmnld.pdf
  • Q1 FY2027 Investor Presentation (Jun 2026, PDF): https://www.stockscans.in/document/jq3m10rpq4gzpvzw01s3fgbe.pdf
  • Q4 FY2026 Investor Presentation (Mar 2026, PDF): https://www.stockscans.in/document/gjchrr1xymmiap5040gux07j.pdf
  • Q3 FY2026 Investor Presentation (Dec 2025, PDF): https://www.stockscans.in/document/w9wu7cf260qrbbnylojwf2z0.pdf
  • Q2 FY2026 Investor Presentation (Sep 2025, PDF): https://www.stockscans.in/document/0r0b3zaz2mvrrqd7ad4sqi55.pdf
  • Q1 FY2026 Investor Presentation (Jun 2025, PDF): https://www.stockscans.in/document/k6wf5q381kkpbg5etslj1at6.pdf
  • Q4 FY2025 Investor Presentation (Mar 2025, PDF): https://www.stockscans.in/document/sck4wyh92soyqnbbgwnqnmbc.pdf
  • Q3 FY2025 Investor Presentation (Dec 2024, PDF): https://www.stockscans.in/document/bwnhzurraa8f08shm16k40o8.pdf
  • Q2 FY2025 Investor Presentation (Sep 2024, PDF): https://www.stockscans.in/document/oirt0uyjsmzlwqct9cp4nzgq.pdf
  • FY2025 Annual Report (PDF): https://www.stockscans.in/document/ozohg5dnbjotjljqp9gcl1z6.pdf
  • FY2024 Annual Report (PDF): https://www.stockscans.in/document/xew8cwyyxrp37irypl8rik22.pdf

Concall Transcript Summaries — Honasa Consumer Ltd

  • Q1 FY2027 Concall Transcript Summary (Jun 2026): https://www.stockscans.in/company/NSE%3AHONASA/transcript-notes/202606/uptjbvgh81ayefu6zfui8t2z.pdf
  • Q4 FY2026 Concall Transcript Summary (Mar 2026): https://www.stockscans.in/company/NSE%3AHONASA/transcript-notes/202603/0hxe1708i2uq82x591pbmzcj.pdf
  • Q3 FY2026 Concall Transcript Summary (Dec 2025): https://www.stockscans.in/company/NSE%3AHONASA/transcript-notes/202512/g1jlmakbmp8ap8a368agcqo4.pdf
  • Q2 FY2026 Concall Transcript Summary (Sep 2025): https://www.stockscans.in/company/NSE%3AHONASA/transcript-notes/202509/t5uzsxuzym0jvfied010pw2n.pdf
  • Q1 FY2026 Concall Transcript Summary (Jun 2025): https://www.stockscans.in/company/NSE%3AHONASA/transcript-notes/202506/i50jycfyqg0g5ytall1cwods.pdf
  • Q4 FY2025 Concall Transcript Summary (Mar 2025): https://www.stockscans.in/company/NSE%3AHONASA/transcript-notes/202503/1jinfimxzwzt24rf4ie9t1n8.pdf
  • Q3 FY2025 Concall Transcript Summary (Dec 2024): https://www.stockscans.in/company/NSE%3AHONASA/transcript-notes/202412/ztnvv0z4c116ym8uhfhldncp.pdf
  • Q2 FY2025 Concall Transcript Summary (Sep 2024): https://www.stockscans.in/company/NSE%3AHONASA/transcript-notes/202409/f7kzowuuc8gvwtccylu1e6up.pdf